Free Trial

Dianthus Therapeutics (DNTH) Stock Price, News & Analysis

Dianthus Therapeutics logo
$23.80 +0.76 (+3.30%)
(As of 12/20/2024 05:16 PM ET)

About Dianthus Therapeutics Stock (NASDAQ:DNTH)

Key Stats

Today's Range
$22.35
$24.22
50-Day Range
$20.27
$29.90
52-Week Range
$7.75
$33.77
Volume
389,926 shs
Average Volume
205,798 shs
Market Capitalization
$704.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.43
Consensus Rating
Buy

Company Overview

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
26th Percentile Overall Score

DNTH MarketRank™: 

Dianthus Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 816th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Dianthus Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Dianthus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dianthus Therapeutics is -9.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dianthus Therapeutics is -9.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dianthus Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    29.30% of the float of Dianthus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dianthus Therapeutics has a short interest ratio ("days to cover") of 22.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dianthus Therapeutics has recently increased by 3.12%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Dianthus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dianthus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    29.30% of the float of Dianthus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dianthus Therapeutics has a short interest ratio ("days to cover") of 22.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dianthus Therapeutics has recently increased by 3.12%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Dianthus Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Dianthus Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dianthus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.56% of the stock of Dianthus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dianthus Therapeutics' insider trading history.
Receive DNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNTH Stock News Headlines

This Crypto Is Set to Explode in December
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Dianthus Therapeutics (DNTH) Receives a Buy from Stifel Nicolaus
Dianthus Therapeutics
See More Headlines

DNTH Stock Analysis - Frequently Asked Questions

Dianthus Therapeutics' stock was trading at $10.40 at the beginning of 2024. Since then, DNTH stock has increased by 128.8% and is now trading at $23.80.
View the best growth stocks for 2024 here
.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) posted its earnings results on Thursday, November, 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.15. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative trailing twelve-month return on equity of 21.68%.

Top institutional shareholders of Dianthus Therapeutics include FMR LLC (14.88%), Janus Henderson Group PLC (3.21%), State Street Corp (2.77%) and Braidwell LP (1.67%). Insiders that own company stock include Fairmount Funds Management Llc and Simrat Randhawa.
View institutional ownership trends
.

Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
11/07/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DNTH
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$46.43
High Stock Price Target
$58.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+95.1%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
10 Analysts

Profitability

Net Income
$-43,560,000.00
Net Margins
-1,250.32%
Pretax Margin
-1,250.32%

Debt

Sales & Book Value

Annual Sales
$5.37 million
Book Value
$11.40 per share

Miscellaneous

Free Float
24,696,000
Market Cap
$704.41 million
Optionable
Optionable
Beta
1.74
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:DNTH) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners